Drug efflux is an important resistance mechanism in Mycobacterium tuberculosis (M. tb.). We found that verapamil, an efflux inhibitor, profoundly decreases the minimum inhibitory concentration of bedaquiline and clofazimine to M. tb. by 8 to 16-fold. This exquisite susceptibility was noted among drug-susceptible and drug-resistant clinical isolates. Thus, efflux inhibition is an important sensitizer of bedaquiline and clofazimine, and efflux may emerge as a resistance mechanism to these drugs.
Verapamil is an FDA approved efflux pump inhibitor that appears promising as adjunctive chemotherapy for TB. We have recently shown that the addition of verapamil accelerates both the bactericidal and sterilizing activities of standard TB treatment in the mouse (6). In an in vitro system, we have shown that after two hours of incubation with verapamil, rifampin levels inside bacterial cells were increased by 2-fold (6). Inhibition of efflux pumps of M. tb. by verapamil reduces the macrophage-induced bacterial drug tolerance in lung granulomas (4) . Lastly, there is evidence that verapamil may reverse some forms of drug-resistance, as it is able to restore rifampin efficacy in mice infected with rifampin-resistant M. tb. strain (7). While the impact of efflux pump inhibition has been demonstrated for rifampin and other first-line medications, it is unclear whether this benefit extends to additional and newer classes of TB drugs. Table 1 .
Eight clinical isolates of M. tb. with various first-and second line drugsusceptibility patterns (see Table 2 ) were obtained from Project SEREFO-NIAID/University of Bamako Research Collaboration on HIV/TB, in Bamako, Mali for evaluation in this study (15, 16) .
We found that supplementation with verapamil profoundly decreases the MIC of bedaquiline among drug-susceptible and drug-resistant clinical isolates. Verapamil yielded an 8 to 16-fold decrease in the bedaquiline MIC of all isolates tested, irrespective of first and second-line drug resistance patterns (See Table 2 ). To confirm these findings, we used a liquid broth dilution assay for MIC determination and obtained similar results.
Similar to bedaquiline, we found that the MIC of clofazimine against M. tb.
decreases by 8-fold in the presence of 50 g/mL verapamil. (See Table 3 This is the first report that efflux pump inhibition by verapamil can potentiate the killing of M. tb. by bedaquiline and clofazimine. In the present study, we found an impressive 8-fold or more reduction in the MICs of bedaquiline and clofazimine, suggesting the specificity of verapamil for inhibiting efflux pumps relevant to these drugs. As with rifampin, verapamil may inhibit the efflux of these drugs from M. tb.
resulting in higher intracellular drug levels and enhanced drug activity.
Our finding that verapamil sensitizes M. tb. to bedaquiline and clofazimine is likely to extend to in vivo infection. By potentiating the killing of bedaquiline and clofazimine, verapamil may accelerate clearance of M. tb., thus allowing for shorter treatment regimens of both drug-susceptible and drug-resistant forms of TB.
Furthermore, given that efflux inhibition renders M. tb. exquisitely susceptible to bedaquiline and clofazamine, these data suggest that efflux may emerge as a common resistance mechanism to these drugs. As has been noted with first-line drugs, verapamil might reduce the macrophage-induced drug tolerance to bedaquiline (4) . As in other organisms (17, 18) , verapamil may prevent the emergence of further drug resistance, and thus preserve the activity bedaquiline. 
